Methods Matter -- Standard Production Platforms For Recombinant AAV Produce Chemically And Functionally Distinct Vectors
Neil G. Rumachik,
Stacy A Malaker,
Lucy H. Maynard,
Christopher M. Adams,
Ryan D. Leib,
Andrew P May,
Nicole K. Paulk
Posted 17 May 2019
bioRxiv DOI: 10.1101/640169 (published DOI: 10.1016/j.omtm.2020.05.018)
Posted 17 May 2019
Different approaches are used in the production of recombinant AAV. The two leading approaches are transiently transfected human HEK293 cells and live baculovirus infection of Sf9 insect cells. Unexplained differences in vector performance have been seen clinically and preclinically. Thus, we performed a controlled comparative production analysis varying only the host cell species but maintaining all other parameters. We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM, denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice. Using these approaches we have made two major discoveries: 1) rAAV capsids have post-translational modifications including glycosylation, acetylation, phosphorylation, and methylation, and these differ between platforms. 2) rAAV genomes are methylated during production, and these are also differentially deposited between platforms. Our data find that host cell protein impurities differ between platforms and can have their own PTMs including potentially immunogenic N-linked glycans. Human-produced rAAVs are more potent than baculovirus-Sf9 vectors in various cell types in vitro (P < 0.05-0.0001), in various mouse tissues in vivo (P < 0.03-0.0001), and in human liver in vivo (P < 0.005). These differences may have clinical implications for rAAV receptor binding, trafficking, expression kinetics, expression durability, vector immunogenicity as well as cost considerations. ### Competing Interest Statement The authors have declared no competing interest.
- Downloaded 6,544 times
- Download rankings, all-time:
- Site-wide: 1,285
- In molecular biology: 20
- Year to date:
- Site-wide: 3,132
- Since beginning of last month:
- Site-wide: 4,503
Downloads over time
Distribution of downloads per paper, site-wide
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!